Waters, D. Higginson, L. et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-68 Disponible en
Waters D, Higginson L, et al. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy.Circulation 1995;92:2404-10 Disponible en
Taylor, AJ; Kent, SM; et al.ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol. A Randomized Trial Comparing the Effects of Atorvastatin and Pravastatin on Carotid Intima Medial Thickness Circulation. 2002;106:2055. Disponible en
Taylor, AJ; Kent, SM; et al.Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2 A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins. Circulation. 2004;110:3512-3517 Disponible en
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters, et al.. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study Investigators. The effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled study. JAMA 2001;285:1711-8. Disponible en
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2.998-3.007. Disponible en
Steven E. Nissen; E. Murat Tuzcu, et al. for the REVERSAL Investigators Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis. A Randomized Controlled Trial JAMA. 2004;291:1071-1080. Disponible en
Pedersen,TR.; Faergeman, O. et al. for the IDEAL study group. High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. JAMA. 2005;294:2437-2445. Disponible en
Crouse JR 3rd, Raichlen JS, Riley WA, et al. METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297:1344–53. Disponible en
David H. Blankenhorn; Stanley P et al. The MARS Research Group. Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS). Annals of Internal Medicine. 1993. Volume 119 Issue 10. Pages 969-976 Disponible en
Berne,C and Siewert,A for the URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovascular Diabetology 2005, 4:7 Disponible en
Michael Donnino and Michael Cocchi, Beth Israel Deaconess Medical Center. Boston, Massachusetts Study of Statin Therapy in the Treatment of Sepsis Estudio randomizado doble ciego iniciado en febrero del 2008. Información disponible en
Ian Ford, Ph.D., Heather Murray, M.Sc.,et al , for the West of Scotland Coronary Prevention Study Group. Long-Term Follow-up of the West of Scotland Coronary Prevention StudyN Engl J Med 2008; 358:193-195, Jan 10, 2008.Disponible en la web en
Cannon CP, Braunwald E, et al, for the Pravastatin or Atorvastatin Evaluation and Infection therapy-Thrombolysis in myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1.495-504 Disponible en
11. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al, for the Treating to New Targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35 Disponible en
Campeau, L Knatterud, GL et al. The Post Coronary Artery Bypass Graft Trial Investigators. The Effect of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation on Obstructive Changes in Saphenous-Vein Coronary-Artery Bypass Grafts. N Engl J Med 1997; 336:1839-1840, Jun 19, 1997 Disponible en
Pitt B, Waters D, et al. Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease. N Engl J Med 1999;341:70 Disponible en
Packard C, Caslake M, Pastor J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol. 2000 Jun 30; 74 Suppl 1: S17-22 Disponible en PMID 10856769
Albert MA, Danielson E, Rifai N, Ridker PM, . Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70. (PMID 11434828)
pubmedcentral.nih.gov
B Jacotot, J D Banga, P Pfister, and M Mehra Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group. Br J Clin Pharmacol. 1994 September; 38(3): 257–263. Disponible en
Lee,CH; de Feyter,P et al. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS) Heart. 2004 October; 90(10): 1156–1161. doi: 10.1136/hrt.2003.027284. Disponible en
Zheng Zhou, Elham Rahme et al. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.CMAJ. 2005 April 26; 172(9): 1187–1194. Disponible en
dailymed.nlm.nih.gov
Daily Med. Current Medication Information. Disponible en
Yasunori Sawayama, Chie Shimizu, et al. Fukuoka atherosclerosis trial (FAST)Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia J Am Coll Cardiol, 2002; 39:610-616 Disponible en
Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110:281–290 Disponible en (enlace roto disponible en Internet Archive; véase el historial, la primera versión y la última).
Stalenhoef AFH, Ballantyne CM, Sarti, C et al. A Comparative study with rosuvastatin in subjects with METabolic Syndrome: rationale and design of the COMETS study. Diabetes Metab 2003;29(Suppl): 4S318 Abstract 2559. Disponible en Archivado el 11 de febrero de 2009 en Wayback Machine.
Packard C, Caslake M, Pastor J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol. 2000 Jun 30; 74 Suppl 1: S17-22 Disponible en PMID 10856769
LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57.Disponioble en la web en «Copia archivada». Archivado desde el original el 12 de febrero de 2009. Consultado el 31 de octubre de 2008.
Alonso Karlezi,R , Mata Pariente,N , Mata López,P;Control de las hiperlipemias en la práctica clínica Rev Esp Cardiol 2007; 6: 24 - 35
ISSN: 1579-2242 Disponible en
Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110:281–290 Disponible en (enlace roto disponible en Internet Archive; véase el historial, la primera versión y la última).
LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57.Disponioble en la web en «Copia archivada». Archivado desde el original el 12 de febrero de 2009. Consultado el 31 de octubre de 2008.
Stalenhoef AFH, Ballantyne CM, Sarti, C et al. A Comparative study with rosuvastatin in subjects with METabolic Syndrome: rationale and design of the COMETS study. Diabetes Metab 2003;29(Suppl): 4S318 Abstract 2559. Disponible en Archivado el 11 de febrero de 2009 en Wayback Machine.
Furberg,CD Adams Jr, HP et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90:1679-1687 Disponible en
